ClinicalTrials.gg
CompletedNCT03946449Updated Oct 15, 2025Results posted

Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)

A Phase 2 interventional study of ARO-AAT in Alpha 1-Antitrypsin Deficiency, sponsored by Arrowhead Pharmaceuticals. Completed at 4 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by Arrowhead Pharmaceuticals · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom — 8 open to participants now, 11 under way, 3 of them phase 3. alpha 1-Antitrypsin Deficiency · United Kingdom.

Enrollment
22nd of 25
16 · median 54
Started
2019
with 2 others
Phase 2
8 of 28
none open now
Registered
9th of 28
by date
Lead sponsor
2 of 28
Arrowhead Pharmaceuticals

Among the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom, this one is the 22nd largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2019, is one of 8 in phase 2, and was the 9th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

8 of the 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in alpha 1-Antitrypsin Deficiency with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the the safety and efficacy of the investigational product, fazirsiran (TAK-999, ARO-AAT), administered subcutaneously to patients with alpha-1 antitrypsin deficiency associated liver disease (AATD).

Read the detailed description

Participants will be enrolled to receive multiple subcutaneous injections of fazirsiran (TAK-999, ARO-AAT). All eligible participants will require a pre-dose biopsy completed as part of the study within the screening window. All participants will undergo an end of study (EOS) biopsy. Treated participants will be offered the opportunity to continue treatment in an open label extension during which they will undergo a final biopsy.

03

Conditions studied

  • Alpha 1-Antitrypsin Deficiency
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of AATD
  • Liver indicating Metavir F1-F3 liver fibrosis based on local pathology read.
  • Women of must have a negative pregnancy test, cannot be breast feeding, and must be willing to use
  • Willing to provide written and to comply with study requirements
  • Non-smoker for at least 1 year
  • No abnormal finding of clinical relevance at screening

Exclusion criteria

Exclusion Criteria:

  • health concerns other than AATD
  • Previous diagnosis or diagnosis at Screening of definitive liver cirrhosis
  • Regular use of alcohol within one month prior to Screening
  • Use of an agent or device within 30 days prior to dosing or current participation in an investigational study involving therapeutic intervention
  • Use of illicit drugs within 1 year prior to Screening

Note: additional inclusion/exclusion criteria may apply, per protocol

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    ARO-AAT 100 mg Cohort 1b

    Primary Study Period (6-12 months): 100 mg dose of subcutaneous ARO-AAT for a minimum of 3 doses, with 2 optional treatment extension periods. Treatment Extension I (12 months): 100 mg dose of subcutaneous AROAAT every 12 weeks (Q12W). Treatment Extension II (up to 24 Months): 100 mg dose of subcutaneous ARO-AAT Q12W.

    Drug: ARO-AAT

  • Experimental
    ARO-AAT 200 mg Cohort 1

    Primary Study Period (6-12 months): 200 mg dose of subcutaneous ARO-AAT for a minimum of 3 doses, with 2 optional treatment extension periods. Treatment Extension I (12 months): 200 mg dose of subcutaneous AROAAT Q12W. Treatment Extension II (up to 24 Months): 200 mg dose of subcutaneous ARO-AAT Q12W.

    Drug: ARO-AAT

  • Experimental
    ARO-AAT 200 mg Cohort 2

    Primary Study Period (6-12 months): 200 mg dose of subcutaneous ARO-AAT for a minimum of 5 doses, with optional treatment extension periods. Treatment Extension I (12 months): 200 mg dose of subcutaneous AROAAT Q12W. Treatment Extension II (up to 24 Months): 200 mg dose of subcutaneous ARO-AAT Q12W.

    Drug: ARO-AAT

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Total Liver Z-AAT, Insoluble Liver-ZAAT, and Soluble Liver Z-AAT at Week 24: Cohorts 1/1b

    Time frame: Baseline, Week 24

  2. Percent Change From Baseline in Total Liver Z-AAT, Insoluble Liver-ZAAT, and Soluble Liver Z-AAT at Week 48: Cohort 2

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Percent Change From Baseline in Serum Z-AAT Over Time: Cohorts 1/1b

    Time frame: Baseline, Weeks 2, 4, 6, 16, 24

  2. Percent Change From Baseline in Serum Z-AAT Over Time: Cohort 2

    Time frame: Baseline, Weeks 2, 4, 6, 16, 22, 28, 34, 40, 48

  3. Alanine Aminotransferase (ALT) Values Over Time: Cohorts 1/1b

    Time frame: Baseline (Day 1), Day 2, Week 2, Week 4, Week 4 (24-48h post dose), Week 6, Week 16, Week 16 (24/48h post dose), Week 24

  4. ALT Values Over Time: Cohort 2

    Time frame: Baseline (Day 1), Day 2, Week 2, Week 4, Week 4 (24-48h post dose), Week 6, Week 16, Week 16 (24/48h post dose), Week 22, Week 28, Week 34, Week 40, Week 48

  5. Gamma Glutamyl Transferase (GGT) Values Over Time: Cohorts 1/1b

    Time frame: Baseline (Day 1), Day 2, Week 2, Week 4, Week 4 (24-48h post dose), Week 6, Week 16, Week 16 (24/48h post dose), Week 24

  6. GGT Values Over Time: Cohort 2

    Time frame: Baseline (Day 1), Day 2, Week 2, Week 4, Week 4 (24-48h post dose), Week 6, Week 16, Week 16 (24/48h post dose), Week 22, Week 28, Week 34, Week 40, Week 48

  7. Fibrosis-4 Index (FIB4) Score Values Over Time: Cohorts 1/1b

    The FIB 4 score evaluates the degree of fibrosis in patients suspected of or already diagnosed with hepatic fibrosis. FIB-4 is calculated as (Age (years) \* aspartate aminotransferase) / (platelets \* √(ALT)). The result provided from the above equation is interpreted according to 2 cut off values: FIB 4 \<1.45 indicates absence of cirrhosis (with a negative predictive value of 90% for advanced fibrosis); FIB 4 between 1.45 - 3.25 are deemed inconclusive; FIB 4 \>3.25 indicates cirrhosis (with a positive predictive value of 65% for advanced fibrosis).

    Time frame: Baseline (Day 1), Day 2 (24-48 hr post-dose), Week 2, Week 4, Week 4 (24-48 hr post-dose), Week 6, Week 16, Week 16 (24-48 hr post-dose), Week 24

  8. FIB4 Score Values Over Time: Cohort 2

    The FIB 4 score evaluates the degree of fibrosis in patients suspected of or already diagnosed with hepatic fibrosis. FIB-4 is calculated as (Age (years) \* aspartate aminotransferase) / (platelets \* √(ALT)). The result provided from the above equation is interpreted according to 2 cut off values: FIB 4 \<1.45 indicates absence of cirrhosis (with a negative predictive value of 90% for advanced fibrosis); FIB 4 between 1.45 - 3.25 are deemed inconclusive; FIB 4 \>3.25 indicates cirrhosis (with a positive predictive value of 65% for advanced fibrosis).

    Time frame: Baseline (Day 1), Day 2 (24-48 hr post-dose), Week 2, Week 4, Week 4 (24-48 hr post-dose), Week 6, Week 16, Week 16 (24-48 hr post-dose), Week 22, Week 28, Week 28 + 1 day, Week 34, Week 40, Week 48

  9. Aspartate Aminotransferase-to-platelet Ratio Index (APRI) Values Over Time: Cohorts 1/1b

    The APRI suggests the level of hepatic fibrosis and possible liver disease. APRI is calculated as 100\*(aspartate aminotransferase/40) / platelets. Scores indicate the following: \< 0.5 = fibrosis is ruled out; 0.5 - 0.7 = associated with some kind of liver damage; 0.7 - 1 = significant fibrosis; \> 1 = associated with cirrhosis.

    Time frame: Baseline (Day 1), Day 2 (24-48 hr post-dose), Week 2, Week 4, Week 4 (24-48 hr post-dose), Week 6, Week 16, Week 16 (24-48 hr post-dose), Week 24

  10. APRI Values Over Time: Cohort 2

    The APRI suggests the level of hepatic fibrosis and possible liver disease. APRI is calculated as 100\*(aspartate aminotransferase/40) / platelets. Scores indicate the following: \< 0.5 = fibrosis is ruled out; 0.5 - 0.7 = associated with some kind of liver damage; 0.7 - 1 = significant fibrosis; \> 1 = associated with cirrhosis.

    Time frame: Baseline (Day 1), Day 2 (24-48 hr post-dose), Week 2, Week 4, Week 4 (24-48 hr post-dose), Week 6, Week 16, Week 16 (24-48 hr post-dose), Week 22, Week 28, Week 34, Week 40, Week 48

  11. N-Terminal Type III Collagen Propeptide (PRO-C3) Values Over Time: Cohorts 1/1b

    PRO-C3 may be a biomarker for the formation of fibrotic tissue in the liver. For serum, the normal range is 6.1 - 13.8 ng/mL (based on a study of human serum samples from healthy men and women). Due to ethnic, dietary and age variations, the reference limits given may not apply to all populations. A reduction in Pro-C3 over time may indicate a reduction in hepatic fibrogenesis.

    Time frame: Baseline, Weeks 4, 16, 24

  12. PRO-C3 Values Over Time: Cohort 2

    PRO-C3 may be a biomarker for the formation of fibrotic tissue in the liver. For serum, the normal range is 6.1 - 13.8 ng/mL (based on a study of human serum samples from healthy men and women). Due to ethnic, dietary and age variations, the reference limits given may not apply to all populations. A reduction in Pro-C3 over time may indicate a reduction in hepatic fibrogenesis.

    Time frame: Baseline, Weeks 4, 16, 28, 40, 48

  13. FibroScan® Values Over Time: Cohorts 1/1b

    FibroScan is a type of liver elastography. Normal results are usually between 2 and 7 kilopascals (kPa), with results higher than the normal range if liver disease is present. The highest possible result is 75 kPa.

    Time frame: Baseline, Week 24

  14. FibroScan® Values Over Time: Cohort 2

    FibroScan is a type of liver elastography. Normal results are usually between 2 and 7 kilopascals (kPa), with results higher than the normal range if liver disease is present. The highest possible result is 75 kPa.

    Time frame: Baseline, Week 24

  15. Portal Inflammation Over Time: Cohorts 1/1b

    Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of portal inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

    Time frame: Baseline, Week 24

  16. Portal Inflammation Over Time: Cohort 2

    Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of portal inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

    Time frame: Baseline, Week 48

  17. Interface Hepatitis Over Time: Cohorts 1/1b

    Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of interface hepatitis, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

    Time frame: Baseline, Week 24

  18. Interface Hepatitis Over Time: Cohort 2

    Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of interface hepatitis, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

    Time frame: Baseline, Week 48

  19. Lobular Inflammation Over Time: Cohorts 1/1b

    Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of lobular inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

    Time frame: Baseline, Week 24

  20. Lobular Inflammation Over Time: Cohort 2

    Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of lobular inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

    Time frame: Baseline, Week 48

  21. Hepatocyte Cell Death Over Time: Cohorts 1/1b

    Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1- point worsening from the baseline category in the liver biopsy parameter of hepatocyte cell death. Hepatocyte Cell Death Score: 0 = No acidophil bodies; 1 = Few acidophil bodies; 2 = Many acidophil. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

    Time frame: Baseline, Week 24

  22. Hepatocyte Cell Death Over Time: Cohort 2

    Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of hepatocyte cell death. Hepatocyte Cell Death Score: 0 = No acidophil bodies; 1 = Few acidophil bodies; 2 = Many acidophil. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

    Time frame: Baseline, Week 48

  23. Meta-analysis of Histological Data in Viral Hepatitis (METAVIR) Fibrosis Stage Score Over Time: Cohorts 1/1b

    Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1- point worsening from the baseline category in the METAVIR fibrosis stage score. The METAVIR scoring system is a system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy of patients with hepatitis C. The stage represents the amount of fibrosis or scarring. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis. F0: no fibrosis F1: portal fibrosis without septa F2: portal fibrosis with few septa F3: numerous septa without cirrhosis F4: cirrhosis

    Time frame: Baseline, Week 24

  24. Meta-analysis of Histological Data in Viral Hepatitis (METAVIR) Fibrosis Stage Score Over Time: Cohort 2

    Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1- point worsening from the baseline category in the METAVIR fibrosis stage score. The METAVIR scoring system is a system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy of patients with hepatitis C. The stage represents the amount of fibrosis or scarring. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis. F0: no fibrosis F1: portal fibrosis without septa F2: portal fibrosis with few septa F3: numerous septa without cirrhosis F4: cirrhosis

    Time frame: Baseline, Week 48

  25. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An Adverse Event (AE) is any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. Serious Adverse Event (SAE) is an AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is a medically important event or reaction. TEAEs are AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. Not related events include those reported as 'Not Related' to study drug. Related events include those reported as 'Possibly Related' or 'Probably Related' to study drug.

    Time frame: From first dose of study drug up to a maximum duration of study follow-up of 202 weeks.

07

Results

Posted Apr 20, 2025

Participant flow

Primary Study Period
Participant flow — Primary Study Period
MilestoneARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1ARO-AAT 200 mg Cohort 2
Started448
Completed448
Not completed000
Treatment Extension I
Participant flow — Treatment Extension I
MilestoneARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1ARO-AAT 200 mg Cohort 2
Started447
Completed447
Not completed000
Treatment Extension II
Participant flow — Treatment Extension II
MilestoneARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1ARO-AAT 200 mg Cohort 2
Started447
Completed444
Not completed003
Withdrew: Rolled over to another study002
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryPercent Change From Baseline in Total Liver Z-AAT, Insoluble Liver-ZAAT, and Soluble Liver Z-AAT at Week 24: Cohorts 1/1b
Time frame:
Baseline, Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Total Liver Z-AAT, Insoluble Liver-ZAAT, and Soluble Liver Z-AAT at Week 24: Cohorts 1/1b
percent changeARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1
Total Liver Z-AAT-83.07 ± 5.830-79.84 ± 10.519
Insoluble Liver-ZAAT-81.58 ± 6.947-12.91 ± 131.702
Soluble Liver Z-AAT-85.36 ± 4.835-88.18 ± 5.718
PrimaryPercent Change From Baseline in Total Liver Z-AAT, Insoluble Liver-ZAAT, and Soluble Liver Z-AAT at Week 48: Cohort 2
Time frame:
Baseline, Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Total Liver Z-AAT, Insoluble Liver-ZAAT, and Soluble Liver Z-AAT at Week 48: Cohort 2
percent changeARO-AAT 200 mg Cohort 2
Total Liver Z-AAT-90.26 ± 9.029
Insoluble Liver-ZAAT-84.83 ± 19.920
Soluble Liver Z-AAT-92.64 ± 7.482
SecondaryPercent Change From Baseline in Serum Z-AAT Over Time: Cohorts 1/1b
Time frame:
Baseline, Weeks 2, 4, 6, 16, 24
Reported as:
Mean · percent change
Percent Change From Baseline in Serum Z-AAT Over Time: Cohorts 1/1b
percent changeARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1
Week 2-69.12 ± 12.381-77.28 ± 7.394
Week 4-80.24 ± 8.880-88.07 ± 4.931
Week 6-87.27 ± 6.140-91.79 ± 3.795
Week 16-78.61 ± 9.186-83.08 ± 6.269
Week 24-83.85 ± 5.426-89.47 ± 3.738
SecondaryPercent Change From Baseline in Serum Z-AAT Over Time: Cohort 2
Time frame:
Baseline, Weeks 2, 4, 6, 16, 22, 28, 34, 40, 48
Reported as:
Mean · percent change
Percent Change From Baseline in Serum Z-AAT Over Time: Cohort 2
percent changeARO-AAT 200 mg Cohort 2
Week 2-72.08 ± 8.645
Week 4-82.22 ± 7.476
Week 6-89.92 ± 4.024
Week 16-85.76 ± 6.106
Week 22-90.87 ± 4.246
Week 28-85.06 ± 7.847
Week 34-89.54 ± 5.434
Week 40-84.12 ± 12.433
Week 48-89.58 ± 5.419
SecondaryAlanine Aminotransferase (ALT) Values Over Time: Cohorts 1/1b
Time frame:
Baseline (Day 1), Day 2, Week 2, Week 4, Week 4 (24-48h post dose), Week 6, Week 16, Week 16 (24/48h post dose), Week 24
Reported as:
Mean · U/L
Alanine Aminotransferase (ALT) Values Over Time: Cohorts 1/1b
U/LARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1
Baseline (Day 1)58.5 ± 41.3687.8 ± 30.42
Day 2 (24-48 hr post-dose)58.5 ± 42.6888.3 ± 32.72
Week 276.5 ± 55.2499.8 ± 53.89
Week 462.3 ± 35.77106.5 ± 42.57
Week 4 (24-48 hr post-dose)60.3 ± 33.9799.0 ± 38.58
Week 649.8 ± 25.1677.0 ± 20.85
Week 1635.7 ± 8.5049.8 ± 5.25
Week 16 (24-48 hr post-dose)31.5 ± 8.8542.7 ± 3.06
Week 2427.8 ± 9.2939.5 ± 3.11
SecondaryALT Values Over Time: Cohort 2
Time frame:
Baseline (Day 1), Day 2, Week 2, Week 4, Week 4 (24-48h post dose), Week 6, Week 16, Week 16 (24/48h post dose), Week 22, Week 28, Week 34, Week 40, Week 48
Reported as:
Mean · U/L
ALT Values Over Time: Cohort 2
U/LARO-AAT 200 mg Cohort 2
Baseline (Day 1)62.1 ± 14.98
Day 2 (24-48 hr post-dose)58.6 ± 15.59
Week 261.9 ± 20.17
Week 455.3 ± 14.09
Week 4 (24-48 hr post-dose)53.0 ± 14.83
Week 654.9 ± 9.79
Week 1639.6 ± 13.13
Week 16 (24-48 hr post-dose)37.5 ± 11.61
Week 2241.0 ± 14.58
Week 2836.7 ± 15.76
Week 3439.4 ± 11.13
Week 4033.4 ± 10.08
Week 4834.5 ± 10.54
SecondaryGamma Glutamyl Transferase (GGT) Values Over Time: Cohorts 1/1b
Time frame:
Baseline (Day 1), Day 2, Week 2, Week 4, Week 4 (24-48h post dose), Week 6, Week 16, Week 16 (24/48h post dose), Week 24
Reported as:
Mean · U/L
Gamma Glutamyl Transferase (GGT) Values Over Time: Cohorts 1/1b
U/LARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1
Baseline (Day 1)70.8 ± 35.30244.8 ± 355.68
Day 2 (24-48 hr post-dose)70.5 ± 39.07247.3 ± 358.01
Week 266.0 ± 37.15210.8 ± 304.4
Week 473.0 ± 43.37222.0 ± 334.85
Week 4 (24-48 hr post-dose)70.0 ± 45.19210.3 ± 312.0
Week 664.0 ± 35.62199.3 ± 292.28
Week 1648.0 ± 23.25135.3 ± 190.31
Week 16 (24-48 hr post-dose)48.0 ± 22.38161.7 ± 212.17
Week 2452.3 ± 28.31112.0 ± 156.92
SecondaryGGT Values Over Time: Cohort 2
Time frame:
Baseline (Day 1), Day 2, Week 2, Week 4, Week 4 (24-48h post dose), Week 6, Week 16, Week 16 (24/48h post dose), Week 22, Week 28, Week 34, Week 40, Week 48
Reported as:
Mean · U/L
GGT Values Over Time: Cohort 2
U/LARO-AAT 200 mg Cohort 2
Baseline (Day 1)62.5 ± 31.09
Day 2 (24-48 hr post-dose)62.1 ± 33.21
Week 260.6 ± 33.14
Week 459.1 ± 49.82
Week 4 (24-48 hr post-dose)57.6 ± 46.91
Week 658.0 ± 36.21
Week 1649.1 ± 36.84
Week 16 (24-48 hr post-dose)48.3 ± 38.68
Week 2248.5 ± 34.85
Week 2844.5 ± 34.62
Week 3445.3 ± 31.37
Week 4045.3 ± 38.20
Week 4848.5 ± 45.05
SecondaryFibrosis-4 Index (FIB4) Score Values Over Time: Cohorts 1/1b

The FIB 4 score evaluates the degree of fibrosis in patients suspected of or already diagnosed with hepatic fibrosis. FIB-4 is calculated as (Age (years) \* aspartate aminotransferase) / (platelets \* √(ALT)). The result provided from the above equation is interpreted according to 2 cut off values: FIB 4 \<1.45 indicates absence of cirrhosis (with a negative predictive value of 90% for advanced fibrosis); FIB 4 between 1.45 - 3.25 are deemed inconclusive; FIB 4 \>3.25 indicates cirrhosis (with a positive predictive value of 65% for advanced fibrosis).

Time frame:
Baseline (Day 1), Day 2 (24-48 hr post-dose), Week 2, Week 4, Week 4 (24-48 hr post-dose), Week 6, Week 16, Week 16 (24-48 hr post-dose), Week 24
Reported as:
Mean · numerical score
Fibrosis-4 Index (FIB4) Score Values Over Time: Cohorts 1/1b
numerical scoreARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1
Baseline (Day 1)1.425 ± 0.36131.583 ± 0.9085
Day 2 (24-48 hr post-dose)1.353 ± 0.26991.618 ± 0.9668
Week 21.580 ± 0.58061.900 ± 1.3056
Week 41.260 ± 0.38401.750 ± 1.3273
Week 4 (24-48 hr post-dose)1.333 ± 0.41941.760 ± 1.3867
Week 61.355 ± 0.46122.013 ± 1.1073
Week 161.257 ± 0.33261.605 ± 1.221
Week 16 (24-48 hr post-dose)1.227 ± 0.22301.940 ± 1.6210
Week 241.265 ± 0.31961.688 ± 1.2563
SecondaryFIB4 Score Values Over Time: Cohort 2

The FIB 4 score evaluates the degree of fibrosis in patients suspected of or already diagnosed with hepatic fibrosis. FIB-4 is calculated as (Age (years) \* aspartate aminotransferase) / (platelets \* √(ALT)). The result provided from the above equation is interpreted according to 2 cut off values: FIB 4 \<1.45 indicates absence of cirrhosis (with a negative predictive value of 90% for advanced fibrosis); FIB 4 between 1.45 - 3.25 are deemed inconclusive; FIB 4 \>3.25 indicates cirrhosis (with a positive predictive value of 65% for advanced fibrosis).

Time frame:
Baseline (Day 1), Day 2 (24-48 hr post-dose), Week 2, Week 4, Week 4 (24-48 hr post-dose), Week 6, Week 16, Week 16 (24-48 hr post-dose), Week 22, Week 28, Week 28 + 1 day, Week 34, Week 40, Week 48
Reported as:
Mean · numerical score
FIB4 Score Values Over Time: Cohort 2
numerical scoreARO-AAT 200 mg Cohort 2
Baseline (Day 1)1.395 ± 0.6634
Day 2 (24-48 hr post-dose)1.543 ± 0.8209
Week 21.383 ± 0.6358
Week 41.420 ± 0.7054
Week 4 (24-48 hr post-dose)1.356 ± 0.6344
Week 61.367 ± 0.6419
Week 161.299 ± 0.5636
Week 16 (24-48 hr post-dose)1.271 ± 0.6521
Week 221.336 ± 0.6269
Week 281.377 ± 0.7152
Week 341.239 ± 0.7527
Week 401.319 ± 0.5782
Week 481.502 ± 0.7680
SecondaryAspartate Aminotransferase-to-platelet Ratio Index (APRI) Values Over Time: Cohorts 1/1b

The APRI suggests the level of hepatic fibrosis and possible liver disease. APRI is calculated as 100\*(aspartate aminotransferase/40) / platelets. Scores indicate the following: \< 0.5 = fibrosis is ruled out; 0.5 - 0.7 = associated with some kind of liver damage; 0.7 - 1 = significant fibrosis; \> 1 = associated with cirrhosis.

Time frame:
Baseline (Day 1), Day 2 (24-48 hr post-dose), Week 2, Week 4, Week 4 (24-48 hr post-dose), Week 6, Week 16, Week 16 (24-48 hr post-dose), Week 24
Reported as:
Mean · numerical score
Aspartate Aminotransferase-to-platelet Ratio Index (APRI) Values Over Time: Cohorts 1/1b
numerical scoreARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1
Baseline (Day 1)0.485 ± 0.22490.745 ± 0.3877
Day 2 (24-48 hr post-dose)0.463 ± 0.21330.753 ± 0.3923
Week 20.633 ± 0.33490.910 ± 0.5231
Week 40.463 ± 0.21850.810 ± 0.4031
Week 4 (24-48 hr post-dose)0.468 ± 0.19210.785 ± 0.4171
Week 60.433 ± 0.16880.918 ± 0.1834
Week 160.343 ± 0.04040.555 ± 0.3008
Week 16 (24-48 hr post-dose)0.330 ± 0.07000.603 ± 0.4203
Week 240.310 ± 0.09700.513 ± 0.2892
SecondaryAPRI Values Over Time: Cohort 2

The APRI suggests the level of hepatic fibrosis and possible liver disease. APRI is calculated as 100\*(aspartate aminotransferase/40) / platelets. Scores indicate the following: \< 0.5 = fibrosis is ruled out; 0.5 - 0.7 = associated with some kind of liver damage; 0.7 - 1 = significant fibrosis; \> 1 = associated with cirrhosis.

Time frame:
Baseline (Day 1), Day 2 (24-48 hr post-dose), Week 2, Week 4, Week 4 (24-48 hr post-dose), Week 6, Week 16, Week 16 (24-48 hr post-dose), Week 22, Week 28, Week 34, Week 40, Week 48
Reported as:
Mean · numerical score
APRI Values Over Time: Cohort 2
numerical scoreARO-AAT 200 mg Cohort 2
Baseline (Day 1)0.500 ± 0.2102
Day 2 (24-48 hr post-dose)0.515 ± 0.2023
Week 20.486 ± 0.1551
Week 40.479 ± 0.2226
Week 4 (24-48 hr post-dose)0.454 ± 0.2127
Week 60.463 ± 0.1678
Week 160.372 ± 0.1812
Week 16 (24-48 hr post-dose)0.358 ± 0.2160
Week 220.386 ± 0.2011
Week 280.387 ± 0.2642
Week 340.379 ± 0.2449
Week 400.349 ± 0.1768
Week 480.440 ± 0.2310
SecondaryN-Terminal Type III Collagen Propeptide (PRO-C3) Values Over Time: Cohorts 1/1b

PRO-C3 may be a biomarker for the formation of fibrotic tissue in the liver. For serum, the normal range is 6.1 - 13.8 ng/mL (based on a study of human serum samples from healthy men and women). Due to ethnic, dietary and age variations, the reference limits given may not apply to all populations. A reduction in Pro-C3 over time may indicate a reduction in hepatic fibrogenesis.

Time frame:
Baseline, Weeks 4, 16, 24
Reported as:
Mean · μg/L
N-Terminal Type III Collagen Propeptide (PRO-C3) Values Over Time: Cohorts 1/1b
μg/LARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1
Baseline16.78 ± 2.96025.15 ± 9.310
Week 416.90 ± 3.53922.10 ± 7.202
Week 1615.60 ± 1.81819.30 ± 0.245
Week 2418.08 ± 2.15916.63 ± 1.621
SecondaryPRO-C3 Values Over Time: Cohort 2

PRO-C3 may be a biomarker for the formation of fibrotic tissue in the liver. For serum, the normal range is 6.1 - 13.8 ng/mL (based on a study of human serum samples from healthy men and women). Due to ethnic, dietary and age variations, the reference limits given may not apply to all populations. A reduction in Pro-C3 over time may indicate a reduction in hepatic fibrogenesis.

Time frame:
Baseline, Weeks 4, 16, 28, 40, 48
Reported as:
Mean · μg/L
PRO-C3 Values Over Time: Cohort 2
μg/LARO-AAT 200 mg Cohort 2
Baseline18.21 ± 3.002
Week 415.81 ± 2.948
Week 1617.03 ± 2.463
Week 2814.31 ± 2.362
Week 4015.10 ± 2.989
Week 4817.09 ± 7.967
SecondaryFibroScan® Values Over Time: Cohorts 1/1b

FibroScan is a type of liver elastography. Normal results are usually between 2 and 7 kilopascals (kPa), with results higher than the normal range if liver disease is present. The highest possible result is 75 kPa.

Time frame:
Baseline, Week 24
Reported as:
Mean · kPa
FibroScan® Values Over Time: Cohorts 1/1b
kPaARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1
Baseline7.28 ± 2.63212.70 ± 6.988
Week 247.30 ± 3.73010.55 ± 5.802
SecondaryFibroScan® Values Over Time: Cohort 2

FibroScan is a type of liver elastography. Normal results are usually between 2 and 7 kilopascals (kPa), with results higher than the normal range if liver disease is present. The highest possible result is 75 kPa.

Time frame:
Baseline, Week 24
Reported as:
Mean · kPa
FibroScan® Values Over Time: Cohort 2
kPaARO-AAT 200 mg Cohort 2
Baseline9.89 ± 3.205
Week 488.67 ± 3.263
SecondaryPortal Inflammation Over Time: Cohorts 1/1b

Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of portal inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Portal Inflammation Over Time: Cohorts 1/1b
percentage of participantsARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1
≥ 1-point improvement25.050.0
no change50.050.0
≥ 1-point worsening25.00.0
SecondaryPortal Inflammation Over Time: Cohort 2

Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of portal inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

Time frame:
Baseline, Week 48
Reported as:
Number · percentage of participants
Portal Inflammation Over Time: Cohort 2
percentage of participantsARO-AAT 200 mg Cohort 2
≥ 1-point improvement12.5
no change37.5
≥ 1-point worsening0.0
Baseline score = 050.0
SecondaryInterface Hepatitis Over Time: Cohorts 1/1b

Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of interface hepatitis, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Interface Hepatitis Over Time: Cohorts 1/1b
percentage of participantsARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1
≥ 1-point improvement50.00.0
no change0.0100.0
≥ 1-point worsening25.00.0
Baseline score = 025.00.0
SecondaryInterface Hepatitis Over Time: Cohort 2

Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of interface hepatitis, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

Time frame:
Baseline, Week 48
Reported as:
Number · percentage of participants
Interface Hepatitis Over Time: Cohort 2
percentage of participantsARO-AAT 200 mg Cohort 2
≥ 1-point improvement25.0
no change25.0
≥ 1-point worsening0.0
Baseline score = 050.0
SecondaryLobular Inflammation Over Time: Cohorts 1/1b

Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of lobular inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Lobular Inflammation Over Time: Cohorts 1/1b
percentage of participantsARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1
≥ 1-point improvement0.00.0
no change25.050.0
≥ 1-point worsening50.050.0
Baseline score = 025.00.0
SecondaryLobular Inflammation Over Time: Cohort 2

Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of lobular inflammation, which was scored on a scale from 0 (none) to 3 (severe). Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

Time frame:
Baseline, Week 48
Reported as:
Number · percentage of participants
Lobular Inflammation Over Time: Cohort 2
percentage of participantsARO-AAT 200 mg Cohort 2
≥ 1-point improvement0.0
no change62.5
≥ 1-point worsening12.5
Baseline score = 025.0
SecondaryHepatocyte Cell Death Over Time: Cohorts 1/1b

Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1- point worsening from the baseline category in the liver biopsy parameter of hepatocyte cell death. Hepatocyte Cell Death Score: 0 = No acidophil bodies; 1 = Few acidophil bodies; 2 = Many acidophil. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Hepatocyte Cell Death Over Time: Cohorts 1/1b
percentage of participantsARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1
≥ 1-point improvement0.00.0
no change25.00.0
≥ 1-point worsening25.025.0
Baseline score = 050.075.0
SecondaryHepatocyte Cell Death Over Time: Cohort 2

Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1-point worsening from the baseline category in the liver biopsy parameter of hepatocyte cell death. Hepatocyte Cell Death Score: 0 = No acidophil bodies; 1 = Few acidophil bodies; 2 = Many acidophil. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis.

Time frame:
Baseline, Week 48
Reported as:
Number · percentage of participants
Hepatocyte Cell Death Over Time: Cohort 2
percentage of participantsARO-AAT 200 mg Cohort 2
≥ 1-point improvement0.0
no change62.5
≥ 1-point worsening0.0
Baseline score = 037.5
SecondaryMeta-analysis of Histological Data in Viral Hepatitis (METAVIR) Fibrosis Stage Score Over Time: Cohorts 1/1b

Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1- point worsening from the baseline category in the METAVIR fibrosis stage score. The METAVIR scoring system is a system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy of patients with hepatitis C. The stage represents the amount of fibrosis or scarring. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis. F0: no fibrosis F1: portal fibrosis without septa F2: portal fibrosis with few septa F3: numerous septa without cirrhosis F4: cirrhosis

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Meta-analysis of Histological Data in Viral Hepatitis (METAVIR) Fibrosis Stage Score Over Time: Cohorts 1/1b
percentage of participantsARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1
≥ 1-point improvement0.050.0
no change100.050.0
≥ 1-point worsening0.00.0
SecondaryMeta-analysis of Histological Data in Viral Hepatitis (METAVIR) Fibrosis Stage Score Over Time: Cohort 2

Percent of participants having ≥ 1-point improvement from baseline, no change from baseline, and ≥ 1- point worsening from the baseline category in the METAVIR fibrosis stage score. The METAVIR scoring system is a system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy of patients with hepatitis C. The stage represents the amount of fibrosis or scarring. Participants with a baseline score of 0 were not included in any of the 3 categories for this analysis. F0: no fibrosis F1: portal fibrosis without septa F2: portal fibrosis with few septa F3: numerous septa without cirrhosis F4: cirrhosis

Time frame:
Baseline, Week 48
Reported as:
Number · percentage of participants
Meta-analysis of Histological Data in Viral Hepatitis (METAVIR) Fibrosis Stage Score Over Time: Cohort 2
percentage of participantsARO-AAT 200 mg Cohort 2
≥ 1-point improvement50.0
no change12.5
≥ 1-point worsening25.0
Baseline score = 012.5
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An Adverse Event (AE) is any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. Serious Adverse Event (SAE) is an AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, Is a medically important event or reaction. TEAEs are AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. Not related events include those reported as 'Not Related' to study drug. Related events include those reported as 'Possibly Related' or 'Probably Related' to study drug.

Time frame:
From first dose of study drug up to a maximum duration of study follow-up of 202 weeks.
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
participantsARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1ARO-AAT 200 mg Cohort 2
≥ 1 TEAE448
≥ 1 Serious TEAE035
TEAE Severity = Mild312
TEAE Severity = Moderate134
TEAE Severity = Severe002
TEAE = Not Related to Study Drug (SD)123
TEAE = Related to SD325
TEAE Injection Site Reaction (ISR) Severity = Mild213
TEAE ISR Severity = Moderate001
TEAE ISR Severity = Severe000
TEAE Leading to SD Discontinuation000
TEAE Requiring Dose Interruption of SD013
TEAE Leading to PRemature Withdrawal From Study000
TEAE Causing Death000

Adverse events

Collected over For a maximum duration of study follow-up of 202 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ARO-AAT 100 mg Cohort 1b0/4 (0%)0/4 (0%)4/4 (100%)
ARO-AAT 200 mg Cohort 10/4 (0%)4/4 (100%)4/4 (100%)
ARO-AAT 200 mg Cohort 20/8 (0%)5/8 (62.5%)8/8 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1ARO-AAT 200 mg Cohort 2
Procedural pneumothoraxInjury, poisoning and procedural complications0/41/40/8
Atrial fibrillationCardiac disorders0/41/40/8
Non-cardiac chest painGeneral disorders0/41/40/8
Viral myocarditisInfections and infestations0/41/40/8
Humerus fractureInjury, poisoning and procedural complications0/40/41/8
SyncopeNervous system disorders0/40/41/8
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/40/41/8
DyspnoeaRespiratory, thoracic and mediastinal disorders0/40/41/8
CholelithiasisHepatobiliary disorders0/40/41/8
DiverticulitisInfections and infestations0/40/41/8
Most frequent other events
Showing 10 of 102
Most frequent other events
EventARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1ARO-AAT 200 mg Cohort 2
NasopharyngitisInfections and infestations3/44/46/8
COVID-19Infections and infestations3/43/44/8
FatigueGeneral disorders2/40/41/8
Blood creatine phosphokinase increasedInvestigations2/41/42/8
DizzinessNervous system disorders2/40/41/8
HeadacheNervous system disorders1/42/41/8
SciaticaNervous system disorders2/40/41/8
EczemaSkin and subcutaneous tissue disorders0/42/40/8
ArthralgiaMusculoskeletal and connective tissue disorders2/41/42/8
Chest painGeneral disorders1/40/43/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)ARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1ARO-AAT 200 mg Cohort 2Total
Mean54.8 ± 10.0144.5 ± 17.0054.6 ± 13.6852.1 ± 14.92
Sex: Female, Male
Sex: Female, Male(Participants)ARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1ARO-AAT 200 mg Cohort 2Total
Female1012
Male34714
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1ARO-AAT 200 mg Cohort 2Total
Hispanic or Latino0000
Not Hispanic or Latino44816
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1ARO-AAT 200 mg Cohort 2Total
White44816
Insoluble Z-Alpha 1 Antitrypsin (Z-AAT)
Insoluble Z-Alpha 1 Antitrypsin (Z-AAT)(nmol/g)ARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1ARO-AAT 200 mg Cohort 2Total
Mean35.9750 ± 16.5169433.2750 ± 53.3101937.4500 ± 27.7307536.0375 ± 31.38345
Soluble Z-AAT
Soluble Z-AAT(nmol/g)ARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1ARO-AAT 200 mg Cohort 2Total
Mean26.3500 ± 5.1881324.3000 ± 10.5889923.3125 ± 7.5991424.3188 ± 7.50984
Total Z-AAT
Total Z-AAT(nmol/g)ARO-AAT 100 mg Cohort 1bARO-AAT 200 mg Cohort 1ARO-AAT 200 mg Cohort 2Total
Mean62.3250 ± 15.8121057.5750 ± 59.6539160.7625 ± 34.0419960.3563 ± 36.13456
08

Study locations

4 sites
  • Research Center 1
    Vienna, 1090, Austria
  • Research Center 1
    Aachen, 52074, Germany
  • Research Center 3
    Cambridge, CB2 0QQ, United Kingdom
  • Research Center 2
    Edinburgh, EH19 3BJ, United Kingdom
09

References and documents

Publications

  • Strnad P, Mandorfer M, Choudhury G, Griffiths W, Trautwein C, Loomba R, Schluep T, Chang T, Yi M, Given BD, Hamilton JC, San Martin J, Teckman JH. Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency. N Engl J Med. 2022 Aug 11;387(6):514-524. doi: 10.1056/NEJMoa2205416. Epub 2022 Jun 25. PubMed 35748699 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Apr 2022, 29 months.

Results were first posted in Apr 2025, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2019
First posted
May 10, 2019
StartActual
Oct 31, 2019
Primary completionActual
Apr 28, 2022
CompletionActual
Dec 14, 2023
Results first posted
Apr 20, 2025
Last update
Oct 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03946449
Responsible party
Sponsor
First posted
May 10, 2019
Start date
Oct 31, 2019
Primary completion
Apr 28, 2022
Completion
Dec 14, 2023
Results posted
Apr 20, 2025
Last update
Oct 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fazirsiran

Start the discussion